Agios surges on Saudi nod, Retail hails ‘Incredible Recovery’
Agios shares rose after Saudi Arabia approved Pyrukynd for thalassemia under its breakthrough program. Retail defended the drug amid FDA concerns over 4 reported deaths, citing patient health conditions. Despite scrutiny, sentiment on Stocktwits turned 'bullish' with 'extremely high' activity. AGIO is up 13.6% YTD.